| Patent application number | Description | Published |
|---|
| 20080269715 | Use of an Adhesive as an Intestinal Barrier for Bariatrics - An apparatus for achieving weight loss in a patient is disclosed. The apparatus has a barrier material and an applicator for dispensing the barrier material about the intestine. An injector is used to place the barrier material to block nutrient transfer from the intestine into the blood stream. The barrier material is a polymerizable adhesive that can be injected interstitially between layers of the intestine, or injected into vascular structures to partially block the flow of blood to the nutrient absorbing layers. | 10-30-2008 |
| 20090120994 | Surgical Fastening Device With Initiator Impregnation of a Matrix or Buttress to Improve Adhesive Application - A material comprising a matrix or a buttress is impregnated with an adhesive initiator and is used with a surgical stapling device and an adhesive. The tissue and material are stapled together, and a knife in the surgical stapling device cuts the tissue and the material. The adhesive is applied across the cut and sets up or polymerizes to seals the cut when the adhesive contacts the adhesive initiator. The surgical stapling device can place the staples in a linear, arcuate, or circular array, and can anastomose luminal tissue. The methods of use can include stapling luminal tissue end to end, stapling two portions of material onto ether side of tissue, and stapling two portions of tissue onto a portion of material. Additionally, a portion of adhesive filed material can be stapled onto one side of portion of tissue and the adhesive initiator impregnated material can be stapled onto the other. Cutting the material and tissue provides a path for the adhesive across the cut, and catalyzes the adhesive from contact with the adhesive initiator. | 05-14-2009 |
| 20090143818 | Use of an Adhesive to Treat Intraluminal Bleeding - A surgical device to stanch the flow of blood is disclosed. The surgical device can place an implantable adhesive over or around varices or other bleeders. The surgical device has a vacuum system for capturing tissue and an adhesive system to apply adhesive to the captured tissue. A vacuum chamber is used to contact tissue and contains a chamber therein for the reception of tissue. An adhesive applicator is provided within the vacuum chamber and moves longitudinally therein to apply adhesive to tissue. The surgical device can apply an adhesive patch to tissue or inject adhesive into tissue. Alternately, an adhesive actuator and a chemical agent can be dispensed to tissue within the vacuum chamber. | 06-04-2009 |
| 20090182195 | ENDOSCOPIC GUIDE SYSTEM - Various devices for use in endoscopic surgery and methods for manufacturing the same are provided. In one embodiment, an endoscopic guide device is provided and includes an injection molded rail and a c-shaped channel defining a track extending through the rail. The channel includes a plurality of slots formed in the c-shaped channel during the injection molding process. A plurality of wings can extend from opposed sides of the c-shaped channel. | 07-16-2009 |
| 20100023044 | ULTRASONIC SURGICAL SHEARS AND TISSUE PAD FOR SAME - An ultrasonic-surgical-shears tissue pad has a tissue-pad body including a base material and at least one filler material. An alternate ultrasonic-surgical-shears tissue pad has a tissue-pad body having adjoining first and second regions, wherein the first region includes a first material and wherein the second region includes a second material. An ultrasonic surgical shears includes an ultrasonic surgical blade and a clamping arm which is operable to open and close toward the blade and which has a transversely and resiliently flexible distal tip. An alternate ultrasonic surgical shears includes an ultrasonic surgical blade, a clamping arm operable to open and close toward the blade, and a tissue pad attached to the clamping arm and having a clamping surface, wherein at least a portion of the tissue pad is resiliently flexible in a direction substantially perpendicular to the clamping surface. | 01-28-2010 |
| 20100222713 | TISSUE PAD FOR USE WITH AN ULTRASONIC SURGICAL INSTRUMENT - An ultrasonic clamp coagulator assembly that is configured to permit selective cutting, coagulation and clamping of tissue during surgical procedures. An elongated portion of the instrument can be configured for endoscopic applications and has an outside diameter of less than 6 mm. The construction includes a clamping mechanism, including a clamp arm pivotally mounted at the distal portion of the instrument, which is specifically configured to create a desired level of tissue clamping forces, exceeding 4 pounds when the trigger is fully closed. The clamping mechanism includes a two-piece pad design and pad material that enables the higher tissue clamping forces and a force-limiting mechanism that effectively smooths out abusive tissue forces. The assembly also features hand activation configured to provide an ergonomical grip and operation for the surgeon. Hand switches are placed in the range of the natural swing of the surgeon's thumb, whether gripping the surgical instrument right-handed or left handed. | 09-02-2010 |
| 20110251612 | ELECTROSURGICAL CUTTING AND SEALING INSTRUMENTS WITH CAM-ACTUATED JAWS - Various embodiments are directed to a surgical instrument comprising, a shaft, and an end effector. The shaft may be coupled to the handle and may extend distally along a longitudinal axis. The end effector may be positioned at a distal end of the shaft and may comprise first and second jaw members and a reciprocating member. The first and second jaw members may define first and second longitudinal slots. One or both of the jaw members may be pivotable relative to the other about a pivot point. The reciprocating member may be translatable distally and proximally parallel to the longitudinal axis and through the first and second longitudinal slots. A distal portion of the reciprocating member may define a blade. The instrument may comprise an overtube translatable distally to exert a force on a portions of the first and second jaw members tending to close the first and second jaw members. | 10-13-2011 |
| 20110282339 | SURGICAL INSTRUMENTS AND END EFFECTORS THEREFOR - Various forms of surgical instruments are disclosed. In various embodiments, an end effector having operable and closable jaws is attached to a distal end of an elongate shaft such that portions of the jaws are axially offset from the elongate shaft. Other jaw embodiments are coupled to an actuation arrangement that permits portions of the jaws to be moved out of axial alignment with the elongate shaft. Other jaw embodiments are configured to facilitate tissue dissection. Electrosurgical instruments are also disclosed. One embodiment employs a flexible electrode that is conformable to tissue. | 11-17-2011 |
| 20110306972 | ELECTROSURGICAL INSTRUMENT EMPLOYING A THERMAL MANAGEMENT SYSTEM - An electrosurgical surgical instrument can comprise a handle and an end effector, wherein the end effector can comprise first and second jaws which can be opened and closed in order to capture tissue therebetween. In various embodiments, the first and second jaws can comprise one or more electrodes configured to apply a voltage across the tissue thereby causing current to flow through the tissue and, as a result, generate heat within the tissue. The surgical instrument can further comprise a fluid circulatory system embedded within at least a portion the end effector wherein, in at least one embodiment, the fluid can be dispensed from the fluid circulatory system and onto the jaws of the end effector and/or the tissue positioned between the jaws. | 12-15-2011 |
| 20120022529 | ELECTROSURGICAL CUTTING AND SEALING INSTRUMENT - A surgical instrument for supplying energy to tissue can comprise a jaw member comprising an electrode, wherein the electrode is configured to supply energy from a power source to captured tissue. The surgical instrument comprises a tissue-cutting element to transect the captured tissue. The rate of distal translation of the tissue-cutting element during the operational stroke may be regulated by at least one electromagnet and at least one electromagnetic engagement surface. | 01-26-2012 |
| Patent application number | Description | Published |
|---|
| 20090082444 | Compositions for the Treatment of Blood Disorders - The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders. | 03-26-2009 |
| 20090220503 | METHOD FOR TREATING CANCERS WITH INCREASED RAS SIGNALING - Disclosed herein are methods for treating a subject with, or at risk for, developing a tumor which has aberrantly increased Ras signaling. The method involves obtaining a biological sample from the subject, determining whether the biological sample contains cells which have aberrantly increased Ras signaling, and administering an agent that selectively inhibits Protein Kinase C (PKC) delta to the subject upon determination of the aberrantly increased Ras signaling, to thereby inhibit PKC-delta in the cell. The increased Ras signaling may result from expression of activated Ras, e.g. resulting from mutations in codon 12, 13, 59, 61, 63, 116, 117, or 146. Such mutations can be determined by detection of a nucleotide sequence encoding an activated form of Ras protein, or by detection of the activated Ras protein. The increased Ras signaling may result from over-expression of wild-type Ras, over-activation of wild-type Ras, or increased activation of one or more effector pathways downstream of Ras. The tumor cells of the individual may be malignant or non-malignant. The inhibitor(s) of PKC-delta may inhibit PKC-delta gene expression, reduce PKC-delta protein levels, and/or inhibit PKC-delta protein function by inhibiting kinase activity. Appropriate inhibitors are Rottlerin, Balanol, balanol analogs, KAI 9S03, and combinations thereof. Also disclosed are methods for determining the likelihood of effectiveness of administering an agent that selectively inhibits PKC-delta to a subject with a tumor. The methods involve determining the presence or absence of aberrantly increased Ras signaling in the tumor, wherein the presence of aberrantly increased Ras signaling indicates that administration of the PKC-delta inhibitor is likely to be effective. | 09-03-2009 |
| 20100280113 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses. | 11-04-2010 |
| 20110086869 | METHODS FOR TREATING VIRAL DISORDERS - Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days. | 04-14-2011 |
| 20110245154 | Methods and Compositions for Treating Viral or Virally-Induced Conditions - Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally. | 10-06-2011 |
| 20110251149 | METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS - Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks. | 10-13-2011 |
| Patent application number | Description | Published |
|---|
| 20110130798 | Dual-Mode Defibrillator Display - A medical device includes a display area that has a thin panel having a substantially flat front surface portion, a translucent layer on a back surface of the thin panel, a layer of text or graphics on a back surface of the translucent layer, and arranged so that the text or graphics is not visible to a user on the front side when light is not provided from inside the device housing, a switch to allow a user to select a first mode or a second mode for the device, and circuitry arranged to energize one or more light sources to provide light from behind the thin panel when the device is in the first mode, and to thereby make visible the text or graphics when the device is in the first mode. | 06-02-2011 |
| 20110130799 | Dual-Mode Defibrillator With Latched Panel - A medical device includes a device housing and a door mounted to the device housing. The device also includes a first magnet mounted to the door, wherein magnetic force applied to the door exerts a moment on the door, and a second magnet mounted in the housing and positioned to hold the door shut by magnetic interaction with the first magnet. In addition, the device includes a user-movable mode-changing mechanism attached to a third magnet, and arranged to hold the third magnet out of proximity with the first and second magnets when the device is in a first mode, and to move the third magnet into proximity with the first and second magnets when the device is in a second mode so as to expel the first magnet away from the housing and open the door to expose items positioned behind the door. | 06-02-2011 |
| Patent application number | Description | Published |
|---|
| 20090038026 | MSCA1 NUCLEOTIDE SEQUENCES IMPACTING PLANT MALE FERTILITY AND METHOD OF USING SAME - Nucleotide sequences of a Msca1 gene, critical to male fertility in plants are described, with DNA molecule and amino acid sequences set forth. Promoter sequences and their essential regions are also identified. The nucleotide sequences are useful in impacting male fertility in plants. | 02-05-2009 |
| 20090038027 | MSCA1 NUCLEOTIDE SEQUENCES IMPACTING PLANT MALE FERTILITY AND METHOD OF USING SAME - Nucleotide sequences of a Msca | 02-05-2009 |
| 20090038028 | MSCA1 NUCLEOTIDE SEQUENCES IMPACTING PLANT MALE FERTILITY AND METHOD OF USING SAME - Nucleotide sequences of a Msca1 gene, critical to male fertility in plants are described, with DNA molecule and amino acid sequences set forth. Promoter sequences and their essential regions are also identified. The nucleotide sequences are useful in impacting male fertility in plants. | 02-05-2009 |
| 20100218276 | MAIZE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN POLYNUCLEOTIDES AND METHODS OF USE - Compositions and methods are provided for modulating the level of phytate in plants. More specifically, the invention relates to methods of modulating the level of phytate utilizing nucleic acids comprising multidrug resistance-associated protein (MRP) nucleotide sequences to modulate the expression of MRP(s) in a plant of interest. The compositions and methods of the invention find use in agriculture for improving the nutritional quality of food and feed by reducing the levels of phytate and/or increasing the levels of non-phytate phosphorus in food and feed. The invention also finds use in reducing the environmental impact of animal waste. | 08-26-2010 |
| 20110173714 | MSCA1 NUCLEOTIDE SEQUENCES IMPACTING PLANT MALE FERTILITY AND METHOD OF USING SAME - Nucleotide sequences of a Msca1 gene, critical to male fertility in plants are described, with DNA molecule and amino acid sequences set forth. Promoter sequences and their essential regions are also identified. The nucleotide sequences are useful in impacting male fertility in plants. | 07-14-2011 |
| 20110191878 | MSCA1 NUCLEOTIDE SEQUENCES IMPACTING PLANT MALE FERTILITY AND METHOD OF USING SAME - Nucleotide sequences of a Msca1 gene, critical to male fertility in plants are described, with DNA molecule and amino acid sequences set forth. Promoter sequences and their essential regions are also identified. The nucleotide sequences are useful in impacting male fertility in plants. | 08-04-2011 |
| 20120058244 | MAIZE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN POLYNUCLEOTIDES AND METHODS OF USE - Compositions and methods are provided for modulating the level of phytate in plants. More specifically, the invention relates to methods of modulating the level of phytate utilizing nucleic acids comprising multidrug resistance-associated protein (MRP) nucleotide sequences to modulate the expression of MRP(s) in a plant of interest. The compositions and methods of the invention find use in agriculture for improving the nutritional quality of food and feed by reducing the levels of phytate and/or increasing the levels of non-phytate phosphorus in food and feed. The invention also finds use in reducing the environmental impact of animal waste. | 03-08-2012 |
